Anticancer agent 164 

CML-IN-1 (compound 7) is a potent anticancer agent. CML-IN-1 displays very good induced-apoptosis effect for human chronic myeloid leukemia (CML) cell line K562. CML-IN-1 exerts its effect via a significantly reduced protein phosphorylation of PI3K/Akt signal pathway. CML-IN-1 (compound 4) also inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer^[1][2].

CML-IN-1 (compound 7) 在细胞检测中表现出最低的细胞毒性和更好的生物活性（K562，IC₅₀：0.038 μM）^[1]。
CML-IN-1 (compound 4) 显着抑制 HCT116 细胞增殖，48 小时后的 IC₅₀ 值分别为 8.04 ± 0.94 µM，72 小时后的 IC₅₀ 值分别为 5.52 ± 0.42 µM^[2]。
CML-IN-1 (compound 4) 以剂量依赖性方式抑制 HCT116 细胞的集落形成、迁移和侵袭，并诱导细胞凋亡并将细胞周期阻滞在 G2/M 期^[2]。
CML-IN-1 (compound 4) 抑制 HCT116 细胞中 MEK/ERK 信号传导的激活^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

540.58

C₂₁H₂₃F₃N₈O₂S₂

2235393-30-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li W, et al. Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1831-1835.  [Content Brief]

  [2]. Li W, et al. A novel 4-(1,3,4-thiadiazole-2-ylthio)pyrimidine derivative inhibits cell proliferation by suppressing the MEK/ERK signaling pathway in colorectal cancer. Acta Pharm. 2023 Sep 14;73(3):489-502.  [Content Brief]